Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues:
Product revenues	$ 9,133	$ 11,623	$ 26,261	$ 27,993
Research and development programs	2,266	5,936	9,483	17,896
Total revenues	11,399	17,559	35,744	45,889
Costs and operating expenses:
Cost of product revenues	4,570	6,598	13,601	14,458
Research and development	13,207	20,571	38,508	63,470
Sales, general and administrative	19,596	25,883	61,845	68,127
Restructuring charges	(21)	0	372	0
Total costs and operating expenses	37,352	53,052	114,326	146,055
Loss from operations	(25,953)	(35,493)	(78,582)	(100,166)
Other income (expense):
Interest and other income, net	315	365	715	993
Interest expense	(3,540)	(3,553)	(10,623)	(9,955)
Loss from equity method investment	(5,916)	(7,201)	(18,291)	(15,313)
Gain from change in fair value of warrant liability	0	0	0	688
Gain from change in fair value of derivative liabilities	176	6,205	27	6,478
Total other income (expense)	(8,965)	(4,184)	(28,172)	(17,109)
Net loss	$ (34,918)	$ (39,677)	$ (106,754)	$ (117,275)
Net loss per share, basic and diluted (in dollars per share)	$ (0.43)	$ (0.50)	$ (1.33)	$ (1.57)
Weighted average number of common shares used in loss per share computation, basic and diluted (in shares)	80,297,757	78,866,597	80,017,436	74,716,284